Review: Cannabis May Alleviate Neuropathic Pain

Share this content:
Review: Cannabis May Alleviate Neuropathic Pain
Review: Cannabis May Alleviate Neuropathic Pain

MONDAY, Aug. 14, 2017 (HealthDay News) -- Cannabis may alleviate neuropathic pain, but is not associated with benefit for adults with posttraumatic stress disorder (PTSD), according to two reviews published online Aug. 15 in the Annals of Internal Medicine.

Shannon M. Nugent, Ph.D., from the VA Portland Health Care System and Oregon Health & Science University, and colleagues conducted a systematic review to examine the benefits of plant-based cannabis preparations for treating chronic pain in adults. The researchers found low-strength evidence that cannabis alleviates neuropathic pain based on 27 chronic pain trials; insufficient evidence was found in other pain populations. Harms in general population studies include increased risk for motor vehicle accidents, psychotic symptoms, and short-term cognitive impairment based on 11 systematic reviews and 32 primary studies.

Maya E. O'Neil, Ph.D., also from the VA Portland Health Care System and Oregon Health & Science University, and colleagues reviewed data from two systematic reviews and from three observational studies to examine the benefits and harms of plant-based cannabis preparations in treating PTSD in adults. The researchers found that there was insufficient evidence from the systematic reviews to draw conclusions about the benefits and harms. Cannabis did not reduce PTSD symptoms compared with nonuse in the observational studies.

"Evidence is insufficient to draw conclusions about the benefits and harms of plant-based cannabis preparations in patients with PTSD, but several ongoing studies may soon provide important results," O' Neil and colleagues write.

Abstract/Full Text - Nugent
Abstract/Full Text - O'Neil
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »